Determine the necessary mass, volume, or concentration for preparing a solution.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Moligand™, 10mM in DMSO Moligand™ für empfindliche chromatographische und analytische Workflows, die minimale Basislinieninterferenzen erfordern.
Store at -80°C Versand Dry ice packs + Cold packs. Genaue Spezifikationen finden Sie im chargenspezifischen COA.
SDS, COA, Datenblatt und Spezifikationsblatt stehen zum Download bereit. Chargenspezifische COA über Chargennummernsuche abrufbar.
In 25 peer-reviewten Publikationen zu Chromatographie, organischer Synthese und Kreuzkupplungsreaktionen zitiert.
Information
Meloxicam Meloxicam is a selective COX inhibitor, used to relieve pain and fever effects.
In vitro
Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture.
In vivo
Meloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model. Meloxicam causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. Meloxicam significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. Meloxicam reduces general MMP activity at PIH 8 and 24 in horse. Meloxicam- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. Meloxicam results in high numbers of neutrophils in ischemia-injured tissue of horse. Meloxicam administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥99%
Umfassendes Dokument zu Gefahren, Handhabung, Lagerung und Einhaltung regulatorischer Vorschriften.
<<<<<<< HEAD SDS herunterladen → ======= SDS herunterladen → >>>>>>> release248-p3Chargenspezifische Qualitätsdaten. Geben Sie Ihre Chargennummer ein, um das genaue COA abzurufen.
COA nachschlagen →Vollständige Qualitätsmerkmale und Akzeptanzkriterien für diese Qualität.
Spezifikationsblatt ansehen →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Schmelzpunkt (°C) | 255°C |
|---|
Unser Leitfaden zur Qualitätsauswahl behandelt Reinheit, Stabilisatorstatus und Anwendungseignung für alle Varianten in unserem Katalog.
Moligand™ Qualitätsleitfaden ansehen →